Correlation between magnetic resonance imaging (MRI) findings and the new bone formation factor Dkk-1 in patients with spondyloarthritis
- PMID: 30206711
- DOI: 10.1007/s10067-018-4284-y
Correlation between magnetic resonance imaging (MRI) findings and the new bone formation factor Dkk-1 in patients with spondyloarthritis
Abstract
In recent years, MRI has been regarded as a major diagnostic tool for spondyloarthritis (SpA), and anti-TNF therapy has been widely confirmed as an effective treatment strategy. This study was designed to investigate the correlation between the secreted protein dickkopf-1 (Dkk-1) and abnormal findings on magnetic resonance imaging (MRI) through a prospective study of 30 cases of SpA. Thirty patients with active SpA were included, all treated with recombinant human tumor necrosis factor (TNF) receptor-antibody fusion protein (YiSaiPu) injection at 50 mg/week for 6 months. All patients were also examined for their clinical, serological, and imaging manifestations of the condition before and after treatment. In patients receiving TNF inhibitor treatment, the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and clinical activity indices BASDAI, BASFI, BASMI, ASDAS-CRP were significantly decreased (p < 0.01). Serum Dkk-1 concentration was also significantly decreased (p < 0.05), as were the scores of bone marrow edema of the sacroiliac joints and the spine (p < 0.05). The score of sacroiliac joint backfill was significantly increased (p < 0.05), and the baseline and changes in the serum Dkk-1 concentration were significantly correlated with the baseline and changes in spinal bone marrow edema levels. Inhibition of the level of serum Dkk-1 by TNF inhibitors may be the molecular basis for inhibiting the formation of new bone in SpA patients. In addition, spinal marrow edema may have significance for predicting new bone formation.
Keywords: Dkk-1; Magnetic resonance imaging (MRI); Spondyloarthritis (SpA); TNF inhibitors.
Similar articles
-
Bone turnover biomarkers, disease activity, and MRI changes of sacroiliac joints in patients with spondyloarthritis.Rheumatol Int. 2020 Dec;40(12):2057-2063. doi: 10.1007/s00296-020-04708-z. Epub 2020 Sep 26. Rheumatol Int. 2020. PMID: 32979065
-
Effects of Anti-Tumor Necrosis Factor Therapy on Osteoblastic Activity at Sites of Inflammatory and Structural Lesions in Radiographic Axial Spondyloarthritis: A Prospective Proof-of-Concept Study Using Positron Emission Tomography/Magnetic Resonance Imaging of the Sacroiliac Joints and Spine.Arthritis Rheumatol. 2022 Sep;74(9):1497-1505. doi: 10.1002/art.42149. Epub 2022 Jul 28. Arthritis Rheumatol. 2022. PMID: 35474641
-
Efficacy of long-term nonsteroidal antiinflammatory drug treatment on magnetic resonance imaging-determined bone marrow oedema in early, active axial spondyloarthritis patients.Clin Rheumatol. 2018 Jan;37(1):245-250. doi: 10.1007/s10067-017-3666-x. Epub 2017 May 11. Clin Rheumatol. 2018. PMID: 28497237
-
Change in MRI in patients with spondyloarthritis treated with anti-TNF agents: systematic review of the literature and meta-analysis.Clin Exp Rheumatol. 2021 Mar-Apr;39(2):242-252. doi: 10.55563/clinexprheumatol/fsluso. Epub 2021 Jan 21. Clin Exp Rheumatol. 2021. PMID: 33506749
-
Emerging Imaging Techniques in Spondyloarthritis: Dual-Energy Computed Tomography and New MRI Sequences.Rheum Dis Clin North Am. 2020 May;46(2):287-296. doi: 10.1016/j.rdc.2020.01.010. Rheum Dis Clin North Am. 2020. PMID: 32340702 Review.
Cited by
-
Current Concepts and Medical Management for Patients with Radiographic Axial Spondyloarthritis.Hip Pelvis. 2024 Dec 1;36(4):234-249. doi: 10.5371/hp.2024.36.4.234. Hip Pelvis. 2024. PMID: 39620565 Free PMC article. Review.
-
Practical Significance of Biomarkers in Axial Spondyloarthritis: Updates on Diagnosis, Disease Activity, and Prognosis.Int J Mol Sci. 2022 Sep 30;23(19):11561. doi: 10.3390/ijms231911561. Int J Mol Sci. 2022. PMID: 36232862 Free PMC article. Review.
-
Comparison of radiological and functional outcomes of conservative treatment with teriparatide and denosumab in thoracolumbar osteoporotic vertebral fracture.Osteoporos Int. 2024 May;35(5):795-804. doi: 10.1007/s00198-024-07025-4. Epub 2024 Jan 23. Osteoporos Int. 2024. PMID: 38261013
-
Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.Nat Rev Rheumatol. 2022 May;18(5):249-257. doi: 10.1038/s41584-022-00764-w. Epub 2022 Mar 10. Nat Rev Rheumatol. 2022. PMID: 35273387 Review.
-
Clinical and Radiological Features Predicting Intervertebral Autofusion after Successful Antibiotic Therapy in Pyogenic Vertebral Osteomyelitis.Diagnostics (Basel). 2021 Jul 27;11(8):1349. doi: 10.3390/diagnostics11081349. Diagnostics (Basel). 2021. PMID: 34441284 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous